|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
GlaxoSmithKline (GSK)'s Dutasteride May Slow Low-Risk Prostate Cancer: Debate Heats Up
1/24/2012 7:39:02 AM
Dutasteride, a drug that is commonly used to treat enlargement of the prostate, might also slow the growth of early-stage prostate cancer and reduce the need for potentially debilitating treatments that carry risks of impotence and incontinence, according to an article published Online First in the Lancet. "Our trial is the first study to show the benefits of use of a 5a-reductase inhibitor to reduce the need for aggressive treatment in men undergoing active surveillance for low-risk prostate cancer…delaying their time to pathological progression and initiation of primary therapy", explains Neil Fleshner from Princess Margaret Hospital, Toronto, Canada, lead author of the study. As many as one in five men in the USA will be diagnosed with prostate cancer, but most will have low-risk (low-volume, low-grade) disease. For these men, active surveillance (conservative management) can be appropriate, and involves forgoing immediate treatment in favour of regular assessment and biopsies to monitor the disease.
|
|
|
|
|
|
|
|
|
|
|